Treatment of Multiple Sclerosis: A Review

Overview

Journal Am J Med

Specialty General Medicine

Date 2020 Jul 20

PMID 32682869

Citations 280

Authors

Stephen L Hauser

Bruce A C Cree

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system, and the leading cause of nontraumatic neurological disability in young adults. Effective management requires a multifaceted approach to control acute attacks, manage progressive worsening, and remediate bothersome or disabling symptoms associated with this illness. Remarkable advances in treatment of all forms of MS, and especially for relapsing disease, have favorably changed the long-term outlook for many patients. There also has been a conceptual shift in understanding the immune pathology of MS, away from a purely T-cell-mediated model to recognition that B cells have a key role in pathogenesis. The emergence of higher-efficacy drugs requiring less frequent administration have made these preferred options in terms of tolerability and adherence. Many experts now recommend use of these as first-line treatment for many patients with early disease, before permanent disability is evident.

Citing Articles

Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort.

Disanto G, Schaedelin S, Oechtering J, Lorscheider J, Galbusera R, Finkener S Mult Scler J Exp Transl Clin. 2025; 11(1):20552173251315457.

PMID: 40017897 PMC: 11866361. DOI: 10.1177/20552173251315457.

Mechanistic insights into connexin-mediated neuroglia crosstalk in neurodegenerative diseases.

Denaro S, DAprile S, Vicario N, Parenti R Front Cell Neurosci. 2025; 19:1532960.

PMID: 40007760 PMC: 11850338. DOI: 10.3389/fncel.2025.1532960.

A Standardized Extract of Roscoe Regulates Clinical and Biological Outcomes in Two Different EAE Mouse Models.

Borgonetti V, Governa P, Morozzi M, Sasia C, Videtta G, Biagi M Biomedicines. 2025; 13(2).

PMID: 40002693 PMC: 11852164. DOI: 10.3390/biomedicines13020278.

Impact of Whole-Body Cryotherapy on Pain, Sleep Quality, Functional Status, and Quality of Life in Multiple Sclerosis: A Comparative Study with Follow-Up.

Zielinska-Nowak E, Lipert A, Kikowski L, Miller E J Pers Med. 2025; 15(2).

PMID: 39997323 PMC: 11856195. DOI: 10.3390/jpm15020046.

Diffuse nuclear Overhauser effect MRI contrast changes detected in multiple sclerosis subjects at 7T.

Jacobs P, Swain A, Wilson N, Liu F, Benyard B, Spangler B Brain Commun. 2025; 7(1):fcaf043.

PMID: 39980739 PMC: 11840165. DOI: 10.1093/braincomms/fcaf043.

References

Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R . Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018; 391(10127):1263-1273. DOI: 10.1016/S0140-6736(18)30475-6. View

Kamm C, Uitdehaag B, Polman C . Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014; 72(3-4):132-41. DOI: 10.1159/000360528. View

Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor B . Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014; 83(11):1022-4. PMC: 4162299. DOI: 10.1212/WNL.0000000000000768. View

Lublin F, Reingold S, Cohen J, Cutter G, Soelberg Sorensen P, Thompson A . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83(3):278-86. PMC: 4117366. DOI: 10.1212/WNL.0000000000000560. View

Calabresi P, Radue E, Goodin D, Jeffery D, Rammohan K, Reder A . Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(6):545-56. DOI: 10.1016/S1474-4422(14)70049-3. View

Cohen J, Comi G, Selmaj K, Bar-Or A, Arnold D, Steinman L . Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019; 18(11):1021-1033. DOI: 10.1016/S1474-4422(19)30238-8. View

Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y . Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler. 2017; 24(7):963-973. PMC: 6029149. DOI: 10.1177/1352458517709619. View

Scannevin R, Chollate S, Jung M, Shackett M, Patel H, Bista P . Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012; 341(1):274-84. DOI: 10.1124/jpet.111.190132. View

Montalban X, Hauser S, Kappos L, Arnold D, Bar-Or A, Comi G . Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2016; 376(3):209-220. DOI: 10.1056/NEJMoa1606468. View

10.

Laroni A, Brogi D, Morra V, Guidi L, Pozzilli C, Comi G . Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol. 2014; 14:65. PMC: 4005629. DOI: 10.1186/1471-2377-14-65. View

11.

Mills E, Mao-Draayer Y . Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. Mult Scler. 2018; 24(8):1014-1022. PMC: 6013383. DOI: 10.1177/1352458518775550. View

12.

Kieseier B . The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011; 25(6):491-502. DOI: 10.2165/11591110-000000000-00000. View

13.

Calabresi P, Kieseier B, Arnold D, Balcer L, Boyko A, Pelletier J . Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014; 13(7):657-65. DOI: 10.1016/S1474-4422(14)70068-7. View

14.

Massacesi L, Genain C, Letvin N, Canfield D, Hauser S . Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis. Ann Neurol. 1995; 37(4):519-30. DOI: 10.1002/ana.410370415. View

15.

Confavreux C, Vukusic S . Natural history of multiple sclerosis: a unifying concept. Brain. 2006; 129(Pt 3):606-16. DOI: 10.1093/brain/awl007. View

16.

Gold R, Kappos L, Arnold D, Bar-Or A, Giovannoni G, Selmaj K . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367(12):1098-107. DOI: 10.1056/NEJMoa1114287. View

17.

Cohen J, Coles A, Arnold D, Confavreux C, Fox E, Hartung H . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856):1819-28. DOI: 10.1016/S0140-6736(12)61769-3. View

18.

Johnson K, Brooks B, Cohen J, Ford C, Goldstein J, Lisak R . Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998; 50(3):701-8. DOI: 10.1212/wnl.50.3.701. View

19.

. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993; 43(4):655-61. DOI: 10.1212/wnl.43.4.655. View

20.

Rudick R, Stuart W, Calabresi P, Confavreux C, Galetta S, Radue E . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):911-23. DOI: 10.1056/NEJMoa044396. View